NCT01447407View on ClinicalTrials.gov

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

December 31, 2012

Conditions
Staphylococcal InfectionsYeast InfectionsCandidiasis
Interventions
BIOLOGICAL

NDV-3 vaccine with alum IM

One dose administered IM

BIOLOGICAL

NDV-3 vaccine without alum IM

One dose administered IM

BIOLOGICAL

Placebo with alum IM

One dose administered ID

BIOLOGICAL

NDV-3 vaccine without alum ID

One dose administered ID

Trial Locations (1)

58104

Cetero Research Clinical Site, Fargo

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

NovaDigm Therapeutics, Inc.

INDUSTRY

NCT01447407 - Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine | Biotech Hunter | Biotech Hunter